Association between atrial fibrillation and <i>Helicobacter pylori</i> by Tetta, Cecilia et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Association between atrial fibrillation and Helicobacter
pylori
Journal Item
How to cite:
Tetta, Cecilia; Moula, Amalia Ioanna; Matteucci, Francesco; Parise, Orlando; Maesen, Bart; Johnson, Daniel;
La Meir, Mark and Gelsomino, Sandro (2019). Association between atrial fibrillation and Helicobacter pylori. Clinical
Research in Cardiology, 108(7) pp. 730–740.
For guidance on citations see FAQs.
c© 2019 The Authors
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1007/s00392-019-01418-w
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Vol:.(1234567890)
Clinical Research in Cardiology (2019) 108:730–740
https://doi.org/10.1007/s00392-019-01418-w
1 3
REVIEW
Association between atrial fibrillation and Helicobacter pylori
Cecilia Tetta1 · Amalia Ioanna Moula1 · Francesco Matteucci1 · Orlando Parise1 · Bart Maesen1 · Daniel Johnson1 · 
Mark La Meir1 · Sandro Gelsomino1 
Received: 5 December 2018 / Accepted: 22 January 2019 / Published online: 8 February 2019 
© The Author(s) 2019
Abstract
The connection between atrial fibrillation (AF) and H. pylori (HP) infection is still matter of debate. We performed a 
systematic review and metanalysis of studies reporting the association between AF and HF. A systematic review of all 
available reports in literature of the incidence of HP infection in AF and comparing this incidence with subjects without 
AF were analysed. Risk ratio and 95% confidence interval (CI) and risk difference with standard error (SE) were the main 
statistics indexes. Six retrospective studies including a total of 2921 were included at the end of the selection process. Nine 
hundred-fifty-six patients (32.7%) were in AF, whereas 1965 (67.3%) were in normal sinus rhythm (NSR). Overall, 335 of 
956 patients with AF were HP positive (35%), whereas 621 were HP negative (65%). In addition, 643 of 1965 NSR patients 
(32.7%) were HP positive while 1,322 were negative (67.3%; Chi-square 2.15, p = 0.21). The Cumulative Risk Ratio for AF 
patients for developing an HP infection was 1.19 (95% CI 1.08–1.41). In addition, a small difference risk towards AF was 
found (0.11 [SE = 0.04]). Moreover, neither RR nor risk difference were influenced by the geographic area at meta-regression 
analysis. Finally, there was a weak correlation between AF and HP (coefficient = 0.04 [95% CI −0.01–0.08]). We failed to 
find any significant correlation between H. pylori infection and AF and, based on our data, it seems unlikely than HP can be 
considered a risk factor for AF. Further larger research is warranted.
Keywords Atrial fibrillation · Helicobacter pylori · Metanalysis
Introduction
Despite better knowledge of the pathophysiology of atrial 
fibrillation(AF) [1–17] and significant advances in ablation 
techniques [18–26], its incidence is rising worldwide [27], 
resulting in a dramatically increased social and economic 
burden on the healthcare system [28–31].
The pathophysiology of AF is complex [32] and it has 
been found to be associated with inflammation as well 
as other non-cardiac pathologies [33–35]. Among these, 
gastrointestinal (GI) disorders share with AF some risk 
factors such as stress, smoking and inflammation as well 
as some common symptoms such as chest pain and faint-
ness [36] and they have often been described in associa-
tion with AF [37].
In particular, Helicobacter pylori (HP) infection has 
been strongly linked to AF by previous studies leading to 
the hypothesis that HP could be the cause of AF through 
systemic inflammatory response [37–39]. Nonetheless, this 
connection has been questioned by other authors and it 
is still matter of debate [40, 41]. Furthermore, available 
metanalyses include other supra-ventricular arrhythmias 
other than AF [42] or include other infections associated 
to AF [39].
Therefore, to test the hypothesis whether there is a causal 
relation between AF and the infection of HP, we performed 
a systematic review and metanalysis of the studies published 
reporting this association.
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to this work.
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Materials and methods
Search strategy
Literature search was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Review and Metanaly-
ses (PRISMA) [43]. An unrestricted literature search was 
performed using PubMed, EMBASE, Web of Science and 
Google Scholar Databases, as well as well as congress pro-
ceedings from major cardio cardiothoracic and cardiology 
societies meetings.
Search terms were: “Atrial Fibrillation” OR “Atrial Fibrilla-
tion AND Gastritis” OR "Atrial Fibrillation AND Helicobac-
ter pylori”, OR “Atrial Fibrillation AND stomach” OR “Atrial 
Fibrillation AND Digestive Disease” OR “Atrial Fibrillation 
AND Digestive Disorders” OR “Arrhythmias AND Gastritis” 
OR "Arrhythmias AND Helicobacter pylori”, OR "Arrhyth-
mias AND stomach” OR "Arrhythmias AND Digestive Dis-
ease” OR "Arrhythmias AND Digestive Disorders”.
The search strategy was decided by two authors (C.T. 
and A.I.M.) and approved by another reviewer (B.M.). The 
literature was limited to articles published in English. Refer-
ences of original articles were reviewed manually and cross-
checked for other relevant reports.
Selection criteria and quality assessment
Studies were included if they met all of the following crite-
ria: (1) human studies; (2) full articles about AF and HP hav-
ing a non-AF control population; (3) adequate information 
regarding the positivity to HP infection. Exclusion criteria 
were: (1) animal studies; (2) case report; reviews; (5) lack 
of information for meta-analysis.
Two authors (A.I.M. and C.T.) selected the study for 
inclusion, extracted studies, as well as patient information 
and outcomes. Two reviewers (S.G. and M.L.M.) indepen-
dently assessed eligibility of the studies and risk of bias. 
Risk of bias at the individual study level was assessed using 
ROBINS-I tool (Risk of Bias in No-randomized Studies-of 
Interventions) [44].
Methodological quality assessment
The quality of included studies was assessed using a rating 
scale based on Downs and Black’s Checklist for Measuring 
Quality [45]. This rating scale for non-randomized designs 
was recently adapted for use in meta-analytic research on 
interpretation biases toward illness-related information [46]. 
The ratings scale consisted of 18 items assessing the quality 
in terms of reporting, external validity, internal validity, con-
founders, and power of the study. Each criterion is rated on a 
two-point scale (0/no, 1/yes), with exception of item 11 (“con-
founders described and controlled for”) that has a score rang-
ing from 0 to 2, with higher scores indicating superior quality. 
Two independent researchers (F.M. and O.P) conducted the 
ratings. Any divergences were resolved by a third reviewer 
(B.M) and quantified using the Cohen’s kappa [47, 48].
Endpoints
The primary endpoint was HP infection defined as diag-
nosed infection either by biopsy-based tests including 
histological evaluation, culture, polymerase chain reac-
tion (PCR), and rapid urease test (RUT) or non-invasive 
procedure such as breath test (UBT), serology, and stool 
antigen test (SAT) [49].
Statistical analysis
Meta-analysis was conducted using Comprehensive Meta-
nalysis v.2.2 (Biostat, Englewood, New Jersey) and Stats 
Direct v.3.0 (Stats Direct Ltd Cambridge, UK). Risk ratio 
and 95% confidence interval (CI) and risk difference with 
standard error (SE) were the main statistics indexes for 
binary outcomes. The statistical inconsistency test  I2 was 
used to assess heterogeneity [50]. Nonetheless, because 
the high degree of heterogeneity anticipated among the 
available studies (only non-randomized trials) and inverse 
variance (DerSimonian Laird) an inverse-variance-ran-
dom effect model was employed as a more conservative 
approach accounting for between- and within-study vari-
ability. Publication bias was evaluated graphically using 
a funnel plot and determined mathematically using Egger 
regression and the Begg–Mazumdar rank correlation test.
A correlation analysis was carried out using the 
Schmidt–Hunter method that provides the least biased esti-
mate [51]. In addition, by means of meta-regression, the 
impact of the geographic area across single studies and its 
relationship to the occurrence of the primary endpoint was 
investigated. All p values < 0.005 were considered statisti-
cally significant.
Results
Characteristics of the studies
The PRISM flow diagram describing the study selection pro-
cess along with reasons for exclusion is shown in Fig. 1. The 
number of studies found was 258. Of these articles 229 were 
excluded as not related to the topic. Twenty-nine articles 
underwent further screening after exclusion of 14 double 
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results, 10 were found to be on topic and suitable for further 
evaluation. One article was added from the references of 
the sources. Subsequently, 11 articles were further assessed. 
Of those four review articles and two articles that did not 
have appropriate end points and/or missing statistical data 
were excluded. After removal of reports not pertinent to the 
design of the current metanalysis, six retrospective observa-
tional studies that met explicit inclusion criteria remained, 
including a total of 2,921 patients [40, 41, 52–56]. Nine 
hundred-fifty-six patients (32.7%) were in AF, whereas 1965 
(67.3%) were in normal sinus rhythm (NSR). Detailed char-
acteristics of studies and patients are described in Table 1.
Methodological quality
The average overall quality rating was 0.81 ± 0.26 with rat-
ings ranging from 0.58 to 1. Table 2 presents the average 
scores on the items of the checklist. The table reveals lower 
scores for the item assessing whether the studies tested par-
ticipants’ engagement with the task(s) and items related to 
the quality of reporting (confounders, exact probability val-
ues, withdrawals/drop-outs, and power analysis). Acceptable 
inter-rater agreement was found (κ = 0.74).
Main endpoint
All the seven selected studies contributed to the analysis. 
Table 3 shows HP diagnostic criteria. In the overall analy-
sis (Fig. 2), 335 of 956 patients with AF were HP positive 
(35%), whereas 621 were HP negative (65%). In addition, 
643 of 1,965 NSR patients (32.7%) were HP positive while 
1322 were negative (67.3%; χ2 2.15, p = 0.21).
The cumulative risk ratio (Fig. 3a) for AF patients for 
developing an HP infection was 1.19 (95% CI 1.08–1.41). 
In addition, a small difference risk (Fig. 3b) towards AF 
was found (RD = 0.11 [SE = 0.04]). Moreover, neither RR 
nor risk difference was influenced by the geographic area 
(Fig. 3c, d) at meta-regression analysis.
There was significant heterogeneity in the selected studies 
(I2 = 63.6%, p = 0.011), thus the random-effect model was 
employed. No publication bias was observed in the funnel 
plot (Fig. 4) and as confirmed in Egger’s test for the asym-
metry (intercept − 0.91, 95% CI − 3.8–5.7, p = 0.62) and 
Begg and Mazumdar test (τ = − 0.04, p = 0.88) that were 
not significant.
Finally, there was a weak correlation (Fig. 5) between AF 
and HP (coefficient = 0.04 [95% CI − 0.01–0.08]). There was 
significant heterogeneity in the selected studies (I2 = 48%, 
p = 0.02) thus the random-effect model was employed (Egg-
er’s test, intercept 1.5, 95% CI − 1.8–4.9, p = 0.30; Begg and 
Mazumdar test, τ = − 0.23, p = 0.45).
Discussion
Helicobacter pylori is a Gram-negative bacterium affecting 
nearly half of the world’s population [49], but only a small 
percentage of infected patients develop more severe patholo-
gies, such as ulcers (10–15%) and stomach adenocarcinomas 
(less than 1%) [57, 58].
The association between atrial fibrillation (AF) and Heli-
cobacter pylori (HP) infection was first reported by Monten-
ero et al. in 2005 who found higher levels of IgG antibodies 
in patients with AF compared to healthy volunteers [37].
This association was believed to be on an inflammatory 
basis and it has been postulated that the infection might 
be the substrate of the systemic inflammation manifest-
ing in AF [38]. Indeed, there is strong evidence to support 
the influence of inflammation in the pathogenesis of atrial 
fibrillation [59] which is associated with increased levels of 
markers which reflect an underlying inflammatory process 
[60]. Actually, the levels of high-sensitivity C-reactive pro-
tein (hs-CRP) have been shown to be higher among patients 
with AF compared with controls in sinus rhythm [60] and 
the stronger association of HP and AF in patients with per-
sistent AF [37] along with the demonstration that persistent 
AF patients have higher hs-CRP levels than paroxysmal AF 
patients [61], would further support the involvement of HP 
in the chronic atrial inflammation resulting in AF. However, 
in contrast with these authors, Marcus et al. [62] failed to 
find any association between atrial fibrillation and all inflam-
matory indices (C-protein, TNF-alpha, CD40 ligand, mono-
cyte chemoattractant protein 1, fibrinogen) excluding IL-6. 
Arcles found 
through PubMed 
n=258 
n=29 
n=10 
n=11 
Total Arcles 
n=6 
Arcles excluded 
Unrelated topics 
n=229 
Double results 
n=14 
Excluded from abstract or lees 
n=5 
Added through 
sources 
n=1 
Reviews excluded 
n=3 
Excluded Lack of evidence 
n=2 
Fig. 1  PRISMA diagram of the study selection process
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A recent study [63] has explained that the development of 
atrial cardiomyopathy, the results of complex of structural, 
architectural, contractile or electrophysiological changes 
affecting the atria, creates a substrate which can maintain 
AF. Nonetheless, not one specific risk factor but multiple 
concomitant modifiable cardiovascular risk factors deter-
mine the manifestation and progression of AF. Recent papers 
identify the alteration of the gut microbiota (dysbiosis) in 
most cardiovascular AF risk factors being responsible of 
AF progression through derived metabolites that affect atrial 
remodeling [64, 65]. Nonetheless, whether and how dysbio-
sis might contribute to atrial remodeling and AF progression 
remains unknown.
Regarding the causal pathophysiologic mechanism, it has 
been postulated that, due to the similarity between H+/K+-
ATPase of gastric and cardiac cells, autoantibodies to H+/
K+-ATPase would hamper the ATP hydrolysis and that this 
unbalance would trigger AF by determining depolarization 
delay and inducing premature atrial contractions [37].
The association of HP and AF was reported also by 
Whang et al. [56] in a Chinese population of 285 patients 
and by Franceschi et al. [55] who found an epidemiologi-
cal link between HP and supraventricular dysrhythmias, 
including AF, and ventricular arrhythmias in 54 arrhythmic 
patients compared to 50 healthy controls. Finally, Bunch 
et al. [52] found that patients with AF were more likely to be 
seropositive for HP than the non-AF-control group. Further-
more, these authors report that younger patients (< 50 years) 
showing a higher risk (8%) of AF of those who were HP 
seropositive. Interestingly, although the oldest group had the 
highest overall incidence of AF, there was, among them, 
only a small increase in risk if they were seropositive for HP.
However, the association between HP and AF has been 
strongly argued by other studies and available reviews and 
metanalyses have not helped to solve the matter because of 
their limitations [39, 42].
For instance, Platonov et al. [41] who have reported no 
significant association between atrial fibrillation and H. 
pylori infection in 72 patients with permanent AF compared 
1:1 to controls, despite significantly higher levels of C-reac-
tive proteins in these subjects. These authors stopped the 
patient recruitment for the study due to a constant reduction 
in differences between groups. In addition, Lunetta et al. [40] 
showed only a small difference in developing AF between 
HP-positive and HP-negative subjects (21% vs. 18%) thus 
excluding that inflammation induced from HP might be 
responsible of new-onset AF.
Our analysis confirms these findings: indeed, the pooled 
HR was very close to one with a 11% risk difference that 
it can be easily influenced by other factors not analyzed by 
papers (sex, familiarity, obesity, race, etc.). Furthermore, we 
found a weak correlation between the infection of HP and 
the development of AF (coefficient = 0.05).Ta
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Therefore, from our data, it seems that there is no strong 
pathogenic link between the bacterial infection and the atrial 
arrhythmias. Hence, it seems more likely that remodeling 
and atrial damage lead to an increase in C-reactive protein 
rather than the opposite. This is also supported by the dem-
onstration that such an increase occurs already at first AF 
onset and in paroxysmal AF [66], thus apparently excluding 
any etiopathogenetic role of the HP.
However, if further studies confirm that HP is not respon-
sible either for the initiation or the maintenance of AF, in 
accordance to our findings, the proposed eradication of HP 
infection as possible treatment for AF patients, proposed by 
some authors [38], it would not be even an option for these 
patients not only for its low cost-effectiveness, but also for 
the risk to further spread antibiotic resistance.
However, when HP arrives in the human stomach, it may 
penetrate the mucin layer and adhere to the gastric epithelial 
cells or it may pass through the stomach without colonizing 
the mucosa. In the stomach, after initial colonization, many 
chemical, biochemical, and immunologic reactions take 
place that are of importance in the progress of the infection 
and the development of disease [67].
In the major part of cases, infections are chronic, whereas 
acute H. pylori disease, lasting for a few weeks, and char-
acterized by abdominal pain and infiltration of polymorph 
nuclear leucocytes in the gastric mucosa, is rarely described 
[67]. All papers included in this review reported HP-IgG-
positivity, therefore we can assume that in all these patients 
B lymphocytes were activated by antigen-presenting cells 
and that a humoral immune response to H. pylori was initi-
ated as response to HP infection.
Finally, an interesting finding of our metanalysis is that, 
in contrast with previous papers [42], the risk ratio of HP 
was not influenced by the geographic area. This difference 
might be due to the inclusion by these authors of one study 
including patients with idiopathic dysrhythmias, leading 
them to different conclusions. Said that our findings need 
to be read with caution since the small number of studies 
coming from Africa and America, these are not surprising. 
Indeed, the H. pylori infection rate is higher in Asia and 
Africa than that in western countries, in relation to differ-
ent standards of hygiene and socioeconomics [5], whereas 
AF shows higher prevalence, disability-adjusted-life years 
(DALYs) and mortality in high-income countries than low-
middle income and developing countries. This difference is 
significant, but it must be interpreted with caution since it 
might be related to under-reporting, limited access to health 
care services and geographically disparity in published data 
[27, 68, 69].
Finally, the higher number of studies coming from west-
ern countries might justify the high AF prevalence reported 
(> 30%) and definitely higher than expected in the gen-
eral population. However, inter-studies heterogeneity also 
regarding AF prevalence variability was addressed by the 
random-effect model used for metanalysis.
Table 2  Quality assessment
All items have a maximum score of 1.00 except item 11 has maximum score of 2.00
Item M SD
1 Study hypothesis/aim/objective described? 1.00 0.00
2 Main outcomes described in the introduction or methods? 0.97 0.16
3 Participant characteristics described? 0.92 0.27
4 Contacted participants representative? 0.87 0.33
5 Prepared participants representative? 0.86 0.35
6 Participants recruited from the same population? 0.70 0.46
7 Participants recruited over the same time? 0.97 0.16
8 Measures and experimental tasks described? 1.00 0.00
9 Main outcome measures valid and reliable? 1.00 0.00
10 Task engagement assessed? 0.33 0.50
11 Confounders described and controlled for? 0.58 0.65
12 Statistical tests appropriate? 1.00 0.00
13 Main findings described? 0.97 0.16
14 Estimates of the random variability in data main outcomes? 0.86 0.35
15 Probability values reported? 0.58 0.50
16 Withdrawals and drop-outs reported? 0.61 0.49
17 Data dredging made clear? 0.92 0.27
18 Sufficient power analysis provided? 0.80 0.27
736 Clinical Research in Cardiology (2019) 108:730–740
1 3
Ta
bl
e 
3 
 H
el
ic
ob
ac
te
r p
yl
or
i i
nf
ec
tio
n d
ata
Nu
m
er
ic 
da
ta 
ar
e r
ep
or
ted
 as
 m
ea
n ±
 st
an
da
rd
 de
vi
ati
on
 or
 (m
ed
ian
). 
Hp
-Ig
G 
an
tib
od
y p
os
iti
vi
ty
 is
 re
po
rte
d a
s n
um
be
r a
nd
 (%
). 
Ca
teg
or
ica
l d
ata
 ar
e r
ep
or
ted
 as
 %
H
p 
Ig
G
 a
nt
ib
od
y 
H
el
ic
ob
ac
te
r 
py
lo
ri
 im
m
un
og
lo
bu
lin
 G
 an
tib
od
y 
(m
g/
L)
, C
ag
A 
H
p-
Ig
G
 a
nt
ib
od
y 
H
el
ic
ob
ac
te
r 
py
lo
ri
 v
iru
len
ce
 fa
cto
r C
ag
A 
(c
yt
ot
ox
in
-a
ss
oc
iat
ed
 g
en
e A
) i
m
m
un
og
lo
bu
lin
 G
 
an
tib
od
y, 
An
ti-
Va
c-
A 
Ig
G
 (m
g/
L)
 an
ti-
H
el
ic
ob
ac
te
r p
yl
or
i v
ac
uo
lat
in
g c
yt
ot
ox
in
 A
W
an
g e
t a
l. 
20
10
Ki
 et
 al
. 2
00
9
Lu
ne
tta
 et
 al
. 2
00
9
Bu
nc
h e
t a
l. 
20
08
 
(n
 =
 83
)
Pl
ato
no
v e
t a
l. 
20
07
Ba
dr
an
. e
t a
l. 
20
07
AF
 (n
 =
 28
5)
Co
nt
ro
ls 
(n
 =
 30
0)
AF
 (n
 =
 60
)
Co
nt
ro
ls 
(n
 =
 36
)
AF
 (n
 =
 39
)
Co
nt
ro
ls 
(n
 =
 14
1)
AF
 (n
 =
 83
)
Co
nt
ro
ls 
(n
 =
 66
0)
AF
 (n
 =
 72
)
Co
nt
ro
ls 
(n
 =
 72
)
AF
 (n
 =
 82
)
Co
nt
ro
ls 
(n
 =
 80
)
NL
SP
LS
P
Hp
-Ig
G 
an
tib
od
y 
po
sit
ive
60
 (4
7.6
)
79
 (4
9.7
)
13
1 (
43
.7)
36
 (6
0.0
)
12
 (3
3.3
)
25
 (6
4.1
)
95
 (6
7.4
)
54
 (6
5.1
)
36
2 (
54
.8)
41
 (5
6.9
)
40
 (5
5.6
)
–
21
 (2
6.3
)
Hp
-Ig
G 
an
ti-
bo
dy
–
–
–
19
.86
 ±
 2.
63
13
.69
 ±
 4.
12
–
–
–
–
–
–
–
–
Hp
-δ
 va
lu
e 
m
ed
ian
[0
.70
0]
[1
.90
]
[0
.62
5]
–
–
–
–
–
–
–
–
–
–
Hp
-δ
 
va
lu
e ≥
 4‰
24
.6
81
.8
28
.7
–
–
–
–
–
–
–
–
–
–
Ca
gA
 H
p-
Ig
G 
an
tib
od
y 
po
sit
ive
–
–
–
–
–
–
–
–
–
–
–
52
 (6
3.4
)
21
 (2
6.3
)
An
ti-
Va
c-A
 
Ig
G
–
–
–
1.5
0 ±
 3.
49
1.0
3 ±
 1.
37
–
–
–
–
–
–
–
–
737Clinical Research in Cardiology (2019) 108:730–740 
1 3
Study limitations
This metanalysis has some limitations that have to be 
pointed out.
Firstly, the number of studies is small, and all papers were 
case–control studies with high-degree of heterogeneity. Sec-
ondly, the number of studies in different geographic areas 
is too small to allow us to draw any final conclusion. Third, 
different diagnostic methods were employed for the diagno-
sis of HP infection and it is not reported if the infection is 
active. Fourth, only a few papers reported the analysis by AF 
type and this did not allow a subgroup analysis. Fifth, moni-
toring and detection of AF was not specified in the studies.
Fig. 2  H. pylori infection in patients with and without AF
Fig. 3  Forest plot. a Risk ratio of HP in patients with AF. b Risk difference of HP incidence between patients with or without AF. c Risk ratio of 
HP in patients with AF by geographic area. d Risk difference of HP incidence between patients with or without AF by geographic area
Fig. 4  Funnel plot
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Conclusions
In conclusion, we did not find any significant correlation 
between H. pylori infection and AF and, based on our data, 
it seems unlikely than HP can be considered a risk factor for 
AF. Further larger research is warranted to establish a poten-
tial role of HP in the pathophysiologic development of AF.
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